Unauthorized Use of Content on this Site: The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB)—including, but not limited to, those available through the PAAB Forum, the PAAB website, and any PAAB correspondence—are specifically intended to assist individuals navigating the PAAB preclearance system. Repurposing or reproducing this content, or using it for model training or any related purposes, is strictly prohibited without the express prior written consent of PAAB. This includes, but is not limited to, the use of such materials in automated systems, machine learning models, or artificial intelligence applications.
First and only claims about dosing regimen?
-
I am wondering if PAAB will allow first and/or only claims regarding dosing regimen (e.g. Drug X: the only treatment for ____ dosed once a month)?
Can you please also clarify the following:
- I assume this will require a "clinical significance unknown" disclaimer, correct?
- Will the full dosing regimen need to appear on the APS as well? Or can we say "for full dosing and administration instructions, please see the Product Monograph?
- What references would be required to support the first/only claim? (Competitor PMs, letter from the manufacturer confirming the claim is true, etc.?)
Thank you!
-
Hey @maryssa
In theory an "only" dosing claim can be made. The specific claim and/or copy required would be assessed during the review based on the indication and limitations of the "only" feature.
-
Yes, a disclaimer is required when making a non-clinical claim. In this example the copy is inherently comparative against the dosing of all other products. The disclaimer would be required to read something similar to “Comparative clinical significance unknown”.
-
The extent of the dosing copy will be dependent on the dosing in the TMA, the overall message of the piece and any class features which may impact the interpretation of the claim. In general, you will also require copy reflective of “for full dosing and administration, please see the Product Monograph”.
-
A letter from medical/regulatory confirming the nature of the “first” and/or “only” claim. The sponsor should also recognize in that letter, that they are aware that it is their responsibility to pull all pieces with this claim from the market if it should no longer be true, regardless of time left in the approval window.
-
